| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0057 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L26-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-33 |
| filingDate |
2021-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ab0d6cea3e4b2d82b6285c444a773fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d2523f177a30a4a0a7a395bc61139d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a6397ed5fa9d62242cf0de104e87899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0730500fe8a60aacd3538981ef48d6f6 |
| publicationDate |
2021-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021256751-A1 |
| titleOfInvention |
Composition comprising fibroblast-derived extracellular vesicle as active ingredient for treating skin and mucosal wound |
| abstract |
The present invention relates to a composition comprising fibroblast-derived extracellular vesicles as an active ingredient for treating skin and mucosal wounds. It is identified that the fibroblast-derived extracellular vesicles are effectively internalized into endothelial cells and fibroblasts to increase the migration of cells to wound sites and induce collagen deposition and maturation thereby effectively promoting would healing at the skin wound sites, and to upregulate the expression of genes involved in inhibiting scar formation in wound sites thereby effectively reducing scarring. Accordingly, the composition comprising fibroblast-derived extracellular vesicles as an active ingredient can be provided as a therapeutic agent for skin and mucosal wounds. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4245306-A1 |
| priorityDate |
2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |